Study to check if giving iron through iv line to patients with low Hb arising due to low iron in the blood before joint replacement surgery decreases the need of giving blood during or after the surgery

Effect of pre-operative optimization of iron deficiency anemia in elective joint replacement patients on transfusion rates

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/11/037850

Enrollment

200

Registered

2021-11-08

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M160- Bilateral primary osteoarthritis of hip Health Condition 2: M170- Bilateral primary osteoarthritis of knee Health Condition 3: M161- Unilateral primary osteoarthritisof hip Health Condition 4: M171- Unilateral primary osteoarthritisof knee

Interventions

Intervention1: Ferric Carboxymaltose: Administration of iv iron (Ferric Carboxymaltose) to patients with iron deficiency anemia in patients undergoing joint replacement surgeries. Ferric Carboxymaltos

the company has no role in design, data-analysis and publication of the study. Intervention2: Ferric Carboxymaltose: Administration of iv iron (Ferric Carboxymaltose) to patients with iron deficiency

the company has no role in design, data-analysis and publication of the study. Dose: 1000mg Frequency and duration of therapy: One dose, 2 weeks before the surgery Route: Intra venous, 1000mg in 100m

Eligibility

Inclusion criteria

Inclusion criteria: Elective primary hip and knee replacement with haemoglobin 10-12 g/dl in females and 10-13 in males with the cause being Iron deficiency anemia

Exclusion criteria

Exclusion criteria: Revision Arthroplasty, Primary Infection, Primary Neoplasm

Design outcomes

Primary

Measure	Time frame
To compare blood transfusion rates after surgery in patients who receives iron transfusion with historical controls Control: Population matching will be done in respect to Age, Sex, Hb/PCV level and the type of surgery done. Timepoint: 2 weeks	—

Secondary

Measure	Time frame
Secondary measures of blood loss like Hb drop, Per op blood loss and cost effectiveness of intervention, post op infection, Length of stay, final hospital bill.Timepoint: 2 weeks	—

Countries

India

Contacts

Public ContactLalmalsawmi Ralte

Department of Orthopaedics, Unit 3, CMCH, Vellore

Alfred_ortho@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026